Table 1.
Characteristics of 271 Participants with Invasive Ovarian Clear Cell Carcinoma
| N (%) | |
|---|---|
|
| |
| Study site (country) | |
| Memorial Sloan Kettering Cancer Center (USA) | 64 (24%) |
| Mayo Clinic (USA) | 56 (21%) |
| Cedars Sinai Medical Center (USA) | 31 (11%) |
| University of Cambridge (United Kingdom) | 27 (10%) |
| University of Pittsburgh (USA) | 23 (9%) |
| Westmead Hospital (Australia) | 22 (8%) |
| Edinburgh (United Kingdom) | 20 (7%) |
| COEUR (Canada) | 13 (5%) |
| Brigham and Women’s Hospital (USA) | 9 (3%) |
| University of Pennsylvania (USA) | 6 (2%) |
| Race, self-reported | |
| White non-Hispanic | 180 (86%) |
| Asian | 25 (12%) |
| Black | 4 (2%) |
| Other/Unknown | 62 |
| Age at diagnosis | |
| Mean (Range), N | 58.1 (31–88), 268 |
| FIGO stage | |
| Early (I, II) | 166 (65%) |
| Advanced (III, IV) | 91 (35%) |
| Unknown | 14 |
| Tumor primary site | |
| Ovary | 209 (88%) |
| Omentum | 4 (2%) |
| Pelvis | 4 (2%) |
| Peritoneum | 3 (1%) |
| Fallopian tube | 1 (<1%) |
| Other | 17 (7%) |
| Unknown | 33 |
| Residual disease | |
| No macroscopic disease | 181 (76%) |
| Macroscopic disease | 57 (24%) |
| Unknown | 33 |
| Prior endometriosis, self-reported | |
| Yes | 33 (23%) |
| No | 108 (77%) |
| Unknown | 130 |
| Primary therapy outcome | |
| Complete response | 157 (80%) |
| Partial response | 7 (4%) |
| Stable disease | 9 (5%) |
| Progressive disease | 23 (12%) |
| Unknown | 75 |
| Progression within five years | |
| Yes | 137 (55%) |
| No | 111 (45%) |
| Unknown | 23 |
| Time to progression among progressors, months | |
| Mean (Range), N | 18.8 (0.03–59.7), 137 |
| Time to last follow-up among non-progressors, months | |
| Mean (Range), N | 51.0 (0.40–60.0), 111 |
| Vital status at five years | |
| Alive | 159 (63%) |
| Deceased | 94 (37%) |
| Unknown | 18 |
| Time to last follow-up among living, months | |
| Mean (Range), N | 45.7 (0.40–60.0), 159 |
COEUR, Canadian Ovarian Experimental Unified Resource; FIGO, International Federation of Gynecology and Obstetrics; residual disease following primary debulking surgery.